Stockreport

Infinity Pharmaceuticals Announces the Initiation of Two Clinical Trials Evaluating IPI-549 in Novel Triple Combination Therapies for the Treatment of Solid Tumors

Infinity Pharmaceuticals, Inc.  (INFI) 
Last infinity pharmaceuticals, inc. earnings: 10/30 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.infi.com/investor-overview
PDF CAMBRIDGE, Mass., Sept. 4, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the initiation of two clinical trials for IPI-549, a first- [Read more]